NL-OMON46055已完成不适用
PD-L1 PET imaging in patients with melanoma or NSCLC with brain metastasis and eligible for treatment with nivolumab - PD-L1 PET imaging in brainmets
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1. Subjects must sign informed consent prior to inclusion in this trial.
- •2. Subjects must be *18 years of age and competent to give informed consent.
- •3. Subjects must be diagnosed with histologically confirmed stage IV melanoma of non-small celllungcancer.
- •4. At least one radiologic new lesion in the brain by MRI, which should be measurable by RANO-BM criteria (longest diameter * 10 mm and perpendicular diameter * 5 mm). Lesions with prior local treatment (i.e., SRT or surgical resection) can be considered measurable if there has been demonstrated progression since the time of local treatment. Leptomeningeal involvement is allowed, but cannot be used as target lesion.
- •5. At least one easy accessible metastatic melanoma lesion of which a biopsy can be taken.
- •6. Subjects must be treatment-naive to nivolumab. (also as adjuvant treatment)
- •7. Subjects must score at least 1 or higher on the Eastern Cooperative Oncology Group (ECOG) Performance Status.(21)
- •8. Subjects must have adequate organ function as defined by the following laboratory values (determined within 28 days prior to randomization/registration):
- •1. White blood cells (WBC) * 2000 /µL
- •2. Absolute neutrophil count (ANC) * 1500 /µL
- •3. Platelets * 100 x103 /µL
- •4. Hemoglobin * 9 g/dL or * 5.6 mmol/L
- •5. Serum creatinine * 1.5 times upper limit of normal (ULN) or creatinine clearance > 40 ml/min (using the Cockcroft-Gault formula)
- •6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) * 3 times ULN
- •7. Bilirubin * 1.5 times ULN (Except patients with the Gilbert Syndrome, for whom a maximum of * 3.0 mg/dL is acceptable)
- •9. Women of childbearing potential (WOCBP) should have a negative urine or serum pregnancy test within 7 days prior to receiving the first administration of nivolumab. Women with non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for * 1 year.
- •10. WOCBP and men who are sexually active with WOCBP must agree to use appropriate method(s) of contraception. (see section 5.2)
排除标准
- •1. Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways, except anti-CTLA4 antibody.
- •2. Subjects who have not recovered to Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Grade 1 or better from the adverse events due to previous cancer therapy.
- •3. Evidence for an active, known or suspected autoimmune disease. Subjects diagnosed with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
- •4. Treatment with corticosteroids in an increasing dosage in the 7 days prior to the first administration of nivolumab. (A stable or decreasing dosage of * 4 mg dexamethasone or equivalent is allowed. In addition, inhaled or topical steroids and adrenal replacement doses are permitted in the absence of active autoimmune disease.)
- •5. Previous malignancies (except non-melanoma skin cancers, in situ bladder cancer, gastric or colon cancers, cervical cancers/dysplasia or breast carcinoma in situ) unless a complete remission was achieved at least 1 years prior to study entry and no additional therapy is required or anticipated to be required during the study period.
- •6. A severe hypersensitivity reaction to prior treatment with a monoclonal antibody, or known hypersensitivity to study drugs components.
- •7. A positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection.
- •8. Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
- •9. Any serious or uncontrolled medical disorder or active infection that, in the opinion of the investigator, may increase the risk associated with study participation, study drug administration, or would impair the ability of the patients to receive protocol therapy.
- •10. A known psychiatric or substance abuse disorder that could interfere with cancer therapy.
- •11. Women of childbearing potential with a positive serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of nivolumab.
- •12. Breastfeeding women.
- •13. Inability to comply with other requirements of the protocol.
研究者
相似试验
进行中（未招募）
1 期
PD-L1 PET imaging study during CAR T-cell therapyPatients with relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of therapy who fulfill the eligibility criteria for CD19-directed CAR T-cell therapy according the Immune Effector Cell Working Group Tumorboard.EUCTR2021-005192-39-NLniversity Medical Center Groningen20
招募中
2 期
Programmed death ligand 1 (PD-L1) PET imaging in patients with (Diffuse) Large B-cell lymphoma who are treated with CD19-directed CAR T-cell therapy: a pilot study.lymphomaNL-OMON56151niversitair Medisch Centrum Groningen20
招募中
不适用
PET/CT Robustness In Melanomamole cancer10040900MelanomaNL-OMON48328Antoni van Leeuwenhoek Ziekenhuis28
进行中（未招募）
1 期
Positron emission tomography (PET) of patients with brain injury and athletes with concussion symptoms - Descriptive study of the tau tracer 18F-RO6958948Traumatic brain injury (TBI), cerebral haemorrhage (ICH), subarachnoid haemorrhage (SAH) and cerebral commotio.MedDRA version: 21.1Level: PTClassification code 10070976Term: Craniocerebral injurySystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 20.1Level: LLTClassification code 10042320Term: Subarachnoid hemorrhageSystem Organ Class: 100000004852MedDRA version: 20.1Level: LLTClassification code 10060690Term: Traumatic brain injurySystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 21.1Level: LLTClassification code 10022754Term: Intracerebral hemorrhageSystem Organ Class: 100000004852EUCTR2020-002433-15-SERegion Skåne80
招募中
不适用
PD-L1 Targeting Molecular Imaging of Solid TumorsGastrointestinal TumorsNCT04629326Peking University Cancer Hospital & Institute20